Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,351Revenue $M269Net Margin (%)-26.6Z-Score9.5
Enterprise Value $M4,002EPS $-0.5Operating Margin %-26.7F-Score4
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-26.6Higher ROA y-yN
Price/Book19.510-y EBITDA Growth Rate %-4.5Quick Ratio3.8Cash flow > EarningsY
Price/Sales15.95-y EBITDA Growth Rate %-16.3Current Ratio4.1Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-15.4Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-31.6Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M123ROI % (ttm)-20.8Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENRay Dalio 2014-06-30 Sold Out -0.01%$32.82 - $46.79
($37.8)
$ 35.25-7%Sold Out0
SGENRay Dalio 2014-03-31 Buy 0.01%$38.57 - $55.14
($47.61)
$ 35.25-26%New holding, 22400 sh.22,400
SGENPRIMECAP Management 2011-06-30 Add0.05%$15 - $21.34
($17.98)
$ 35.2596%Add 21.21%9,572,853
SGENPRIMECAP Management 2011-03-31 Add0.04%$13.95 - $17.23
($15.41)
$ 35.25129%Add 29.25%7,897,953
SGENPRIMECAP Management 2010-12-31 Add0.06%$13.77 - $17.35
($15.64)
$ 35.25125%Add 77.8%6,110,600
SGENPRIMECAP Management 2010-09-30 Buy 0.09%$11.44 - $15.08
($12.22)
$ 35.25188%New holding, 3436800 sh.3,436,800
SGENJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.84)
$ 35.25225%Sold Out0
SGENJean-Marie Eveillard 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 35.25264%New holding, 67373 sh.67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 35.25202%Sold Out0
SGENJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.08)
$ 35.25288%Sold Out0
SGENJean-Marie Eveillard 2009-03-31 Add$7.23 - $10.36
($9.4)
$ 35.25275%Add 40%70,000
SGENJean-Marie Eveillard 2008-12-31 Buy 0.01%$7.76 - $10.6
($8.9)
$ 35.25296%New holding, 50000 sh.50,000
SGENJean-Marie Eveillard 2008-09-30 Sold Out $8.23 - $12.97
($11)
$ 35.25220%Sold Out0
SGENJean-Marie Eveillard 2008-06-30 Buy $8.79 - $10.59
($9.6)
$ 35.25267%New holding, 60000 sh.60,000
SGENJean-Marie Eveillard 2007-06-30 Sold Out -0.01%$8.48 - $10.41
($9.7)
$ 35.25263%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SGEN PRIMECAP Management 2014-06-3010,895,8008.830.46-1.01%
SGEN Ray Dalio 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
SIEGALL CLAY BPresident and CEO 2014-09-04Sell5,600$42.54-18.55view
DOBMEIER ERICCOO 2014-08-25Sell4,818$43.55-20.44view
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci. 2014-08-24Sell3,310$43.55-20.44view
BOERNER CHRISTOPHER S.Executive Vice President, Comm 2014-08-24Sell1,248$43.55-20.44view
DRACHMAN JONATHAN GCMO & EVP, R & D 2014-08-24Sell2,772$43.55-20.44view
SIMPSON TODD ECFO 2014-08-24Sell3,696$43.55-20.44view
SIEGALL CLAY BPresident and CEO 2014-08-24Sell25,507$43.55-20.44view
SIEGALL CLAY BPresident and CEO 2014-08-12Sell11,200$40.38-14.19view
BAKER FELIXDirector, 10% Owner 2014-06-13Buy216,595$39.92-13.2view
SIEGALL CLAY BPresident and CEO 2014-06-10Sell11,200$40.14-13.68view

Press Releases about SGEN :

Quarterly/Annual Reports about SGEN:

    News about SGEN:

    Articles On GuruFocus.com
    Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
    Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
    Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
    Comment for Companies Ranked by Business Predictability Jan 03 2013 
    Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
    WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
    Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: SGEN, APKT, AMRC, FNGN Oct 10 2011 
    Weekly CEO Sells Highlight: WLL, PDE, HUM, SGEN Mar 20 2011 

    More From Other Websites
    Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths Oct 15 2014
    Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter 2014 Financial... Oct 14 2014
    Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma Oct 03 2014
    The Zacks Analyst Blog Highlights: Super Micro Computer, Horizon Pharma, Phibro Animal Health,... Oct 02 2014
    Will This Analyst Downgrade Hurt Seattle Genetics (SGEN) Stock Today? Sep 30 2014
    SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 29 2014
    Seattle Genetics Seeks Expanded Use of Lymphoma Drug on Study Win Sep 29 2014
    Seattle Genetics and Takeda's cancer drug meets main trial goal Sep 29 2014
    Seattle Genetics ADCETRIS phase 3 AETHERA clinical trial top-line results Call scheduled for 8:30 am... Sep 29 2014
    Seattle Genetics, Takeda's cancer drug meets main goal in trial Sep 29 2014
    Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS®... Sep 29 2014
    Seattle Genetics and Takeda Announce Positive Data from Phase 3 AETHERA Clinical Trial of ADCETRIS®... Sep 29 2014
    Seattle Genetics to Host Conference Call and Webcast on September 29, 2014 Regarding Top-line Data... Sep 26 2014
    Seattle Genetics' Adcetris Positive in Durability Analysis Sep 25 2014
    Cramer: What caused today's rally Sep 24 2014
    Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from... Sep 24 2014
    Seattle Genetics-Genmab Expand Deal for Antibody Platform Sep 11 2014
    Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration Sep 10 2014
    Seattle Genetics to Present at Morgan Stanley Healthcare Conference Sep 02 2014
    Will Seattle Genetics (SGEN) Crush Estimates at Its Next Earnings Report? Aug 29 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK